ES525228A0 - Un metodo para preparar una solucion acuosa estable que contiene factor de necrosis de tumores. - Google Patents
Un metodo para preparar una solucion acuosa estable que contiene factor de necrosis de tumores.Info
- Publication number
- ES525228A0 ES525228A0 ES525228A ES525228A ES525228A0 ES 525228 A0 ES525228 A0 ES 525228A0 ES 525228 A ES525228 A ES 525228A ES 525228 A ES525228 A ES 525228A ES 525228 A0 ES525228 A0 ES 525228A0
- Authority
- ES
- Spain
- Prior art keywords
- preparing
- aqueous solution
- solution containing
- necrosis factor
- tumor necrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/04—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Dentistry (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57149890A JPS5939829A (ja) | 1982-08-31 | 1982-08-31 | ガン壊死因子安定化法 |
JP57172178A JPS5959625A (ja) | 1982-09-28 | 1982-09-28 | ガン壊死因子を安定化する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES525228A0 true ES525228A0 (es) | 1987-06-16 |
ES8706446A1 ES8706446A1 (es) | 1987-06-16 |
Family
ID=26479654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES525228A Expired ES8706446A1 (es) | 1982-08-31 | 1983-08-30 | Un metodo para preparar una solucion acuosa estable que contiene factor de necrosis de tumores. |
Country Status (6)
Country | Link |
---|---|
US (1) | US4457916A (es) |
DE (1) | DE3331003C2 (es) |
ES (1) | ES8706446A1 (es) |
FR (1) | FR2532178B1 (es) |
GB (1) | GB2126588B (es) |
IT (1) | IT1200970B (es) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4920196A (en) * | 1982-07-30 | 1990-04-24 | Genentech, Inc. | Human lymphotoxin |
CA1213827A (en) * | 1983-04-29 | 1986-11-12 | Ricardo H. Landaburu | Process for pasteurizing fibronectin |
GB2187191B (en) * | 1984-01-30 | 1989-11-01 | Quadrant Bioresources Ltd | Protection of proteins and the like |
DE3583880D1 (de) * | 1984-04-09 | 1991-10-02 | Takeda Chemical Industries Ltd | Stabile interleukin-2-zusammensetzung. |
JPS60258125A (ja) * | 1984-06-06 | 1985-12-20 | Hayashibara Biochem Lab Inc | 蛋白性生理活性物質を含有する水溶性乾燥物 |
US6686455B1 (en) * | 1984-07-05 | 2004-02-03 | Genentech, Inc. | Tumor necrosis factor |
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US4650674A (en) * | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
US5840522A (en) * | 1984-09-20 | 1998-11-24 | Chiron Corporation | Recombinant lectins |
US4677064A (en) * | 1984-11-09 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
JPS61108400A (ja) * | 1984-10-31 | 1986-05-27 | Amano Pharmaceut Co Ltd | コレステロ−ルの定量法 |
US4743680A (en) * | 1985-02-01 | 1988-05-10 | New York University | Method for purifying antihemophilic factor |
US5266333A (en) * | 1985-03-06 | 1993-11-30 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone |
EP0193917A3 (en) * | 1985-03-06 | 1987-09-23 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration |
US6084073A (en) * | 1985-03-25 | 2000-07-04 | Chiron Corporation | Recombinant ricin toxin |
US4684623A (en) * | 1985-05-02 | 1987-08-04 | The Board Of Trustees Of The Cetus Corporation | Use of tumor necrosis factor as a weight regulator |
US4931385A (en) * | 1985-06-24 | 1990-06-05 | Hygeia Sciences, Incorporated | Enzyme immunoassays and immunologic reagents |
DE229810T1 (de) * | 1985-07-09 | 1987-11-05 | Quadrant Bioresources Ltd., Soulbury, Leighton Buzzard, Bedfordshire | Beschuetzung von proteinen und aehnlichem. |
US4868108A (en) * | 1985-12-12 | 1989-09-19 | Hygeia Sciences, Incorporated | Multiple-antibody detection of antigen |
US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
GB8604983D0 (en) * | 1986-02-28 | 1986-04-09 | Biocompatibles Ltd | Protein preservation |
HU198626B (en) * | 1986-05-27 | 1989-11-28 | Sandoz Ag | Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient |
US4762857A (en) * | 1986-05-30 | 1988-08-09 | E. I. Du Pont De Nemours And Company | Trehalose as stabilizer and tableting excipient |
US4678812A (en) * | 1986-05-30 | 1987-07-07 | E. I. Du Pont De Nemours And Company | Trehalose as stabilizer and tableting excipient |
CA1292686C (en) * | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
US5183746A (en) * | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
US5037644A (en) * | 1986-10-27 | 1991-08-06 | Cetus Corporation | Pharmaceutical compositions of recombinant interleukin-2 and formulation processes |
ATE195022T1 (de) | 1987-04-27 | 2000-08-15 | Unilever Nv | Spezifische bindungstestverfahren |
US4808402A (en) * | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
CA1327161C (en) * | 1987-09-01 | 1994-02-22 | Mitsugu Kobayashi | Lyophilized pharmaceutical composition of neocarzinostatin derivative |
US5756450A (en) * | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
US5215743A (en) * | 1988-04-13 | 1993-06-01 | Maninder Singh | Tumor necrosis factor formulations |
US5078997A (en) * | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
US5221616A (en) * | 1988-07-15 | 1993-06-22 | Quidel Corporation | Prevention of spontaneous complement activation in mammalian biological fluids |
US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5102788A (en) * | 1988-11-21 | 1992-04-07 | Hygeia Sciences, Inc. | Immunoassay including lyophilized reactant mixture |
US5223395A (en) * | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
USRE39497E1 (en) | 1989-02-16 | 2007-02-27 | Nektar Therapeutics | Storage of materials |
US6352862B1 (en) | 1989-02-17 | 2002-03-05 | Unilever Patent Holdings B.V. | Analytical test device for imuno assays and methods of using same |
US5270057A (en) * | 1990-03-20 | 1993-12-14 | Akzo N.V. | Stabilized gonadotropin containing preparations |
US5384132A (en) * | 1990-03-20 | 1995-01-24 | Akzo N.V. | Stabilized gonadotropin containing preparations |
TW282399B (es) * | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
US5653974A (en) * | 1990-10-18 | 1997-08-05 | Board Of Regents,The University Of Texas System | Preparation and characterization of liposomal formulations of tumor necrosis factor |
AU659645B2 (en) * | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
US5342612A (en) * | 1991-12-20 | 1994-08-30 | American Cyanamid Company | Compositions for the treatment of mammalian diseases |
EP0713397B1 (en) * | 1992-03-24 | 2002-12-11 | United Cancer Research Institute | Vaccine containing live virus |
IT1254359B (it) * | 1992-05-11 | 1995-09-14 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti il-6 |
US6509006B1 (en) | 1992-07-08 | 2003-01-21 | Inhale Therapeutic Systems, Inc. | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
PL179443B1 (pl) | 1994-03-07 | 2000-09-29 | Inhale Therapeutic Syst | Kompozycja insuliny, sposób wytwarzania kompozycji insuliny i sposób wytwarzania dawki insuliny w postaci aerozolu PL PL PL PL |
EP0763056B1 (en) * | 1994-03-16 | 2000-08-09 | Mallinckrodt Inc. | Use of surfactants for stabilization of peptides and proteins for radiopharmaceutical use |
WO1995033488A1 (en) * | 1994-06-02 | 1995-12-14 | Quadrant Holdings Cambridge Limited | Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
US6080707A (en) * | 1995-02-15 | 2000-06-27 | The Procter & Gamble Company | Crystalline hydroxy waxes as oil in water stabilizers for skin cleansing liquid composition |
BR9607609A (pt) * | 1995-02-15 | 1998-06-09 | Procter & Gamble | Composição líquida ara limpeza da pele de formação de espuma de intensidade estável e conjunto de banho de asseio do corpo |
ATE227560T1 (de) * | 1995-03-14 | 2002-11-15 | Procter & Gamble | Dispergierter smektit-ton als öl-in-wasser stabilisator für flüssige hautreinigungszusammensetzung |
DE69618767T2 (de) | 1995-03-14 | 2002-12-05 | Procter & Gamble | Dispergierte,amorphe kieselsäure als öl-in-wasser stabilisator für flüssige hautreinigungszusammensetzung |
US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
GB9508691D0 (en) | 1995-04-28 | 1995-06-14 | Pafra Ltd | Stable compositions |
US6632648B1 (en) * | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
US5876992A (en) | 1996-07-03 | 1999-03-02 | Molecular Biology Resources, Inc. | Method and formulation for stabilization of enzymes |
TW518235B (en) * | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
US6558901B1 (en) * | 1997-05-02 | 2003-05-06 | Biomerieux Vitek | Nucleic acid assays |
IL124275A (en) * | 1997-05-02 | 2002-03-10 | Bio Merieux Vitek Inc | A method to produce sequences of nucleic acids |
US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
DE19758073A1 (de) * | 1997-12-30 | 1999-07-01 | Schleuning Michael Priv Doz Dr | Verfahren zur Kryokonservierung menschlicher und tierischer hämatopoetischer Zellen |
US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
CN1258379C (zh) * | 2000-02-08 | 2006-06-07 | 阿勒根公司 | 肉毒杆菌毒素药物组合物 |
US20030138460A1 (en) * | 2000-02-08 | 2003-07-24 | Allergan, Inc | Methods of treating animals with botulinum toxin pharmaceutical compositions |
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
DK1280520T4 (en) | 2000-05-10 | 2018-06-25 | Novartis Ag | Phospholipid based powders for drug delivery |
WO2003035673A1 (en) | 2001-10-22 | 2003-05-01 | Dompe S.P.A. | Supercritical fluids processing: preparation of protein microparticles and their stabilisation |
EP1458360B1 (en) | 2001-12-19 | 2011-05-11 | Novartis AG | Pulmonary delivery of aminoglycosides |
US7582313B2 (en) | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
US7628988B2 (en) * | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
US20040229785A1 (en) * | 2002-11-15 | 2004-11-18 | Denise Faustman | Screening methods to identify treatments for autoimmune disease |
DE60333228D1 (de) * | 2002-12-02 | 2010-08-12 | Amgen Fremont Inc | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen |
KR100560697B1 (ko) * | 2003-08-06 | 2006-03-16 | 씨제이 주식회사 | 알부민을 함유하지 않는 에리스로포이에틴 제제 |
RU2386638C2 (ru) * | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
GB2416122A (en) | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
US20080102054A1 (en) * | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
KR101354093B1 (ko) | 2005-03-14 | 2014-01-24 | 와이어쓰 엘엘씨 | 티게사이클린 조성물 및 이의 제조방법 |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
FR2902341B1 (fr) * | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
FR2910327B1 (fr) * | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
US8187799B2 (en) | 2007-04-26 | 2012-05-29 | Bayer Healthcare Llc | Stabilization of liquid solutions of recombinant protein for frozen storage |
FR2930447B1 (fr) * | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
JP2011520889A (ja) * | 2008-05-15 | 2011-07-21 | バクスター・インターナショナル・インコーポレイテッド | 安定な医薬製剤 |
JP5721704B2 (ja) | 2009-06-12 | 2015-05-20 | マイクロニクス, インコーポレイテッド | マイクロ流体デバイス内のtaqポリメラーゼを乾燥保存するための再水和可能なマトリックス |
CN102803507B (zh) | 2009-06-12 | 2016-05-25 | 精密公司 | 用于微流体装置中在板反应剂的脱水储存的组合物及方法 |
EP2953634B1 (en) | 2013-02-07 | 2021-05-26 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
EP3447075B1 (en) | 2015-05-15 | 2023-08-09 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
US11266730B2 (en) | 2015-09-29 | 2022-03-08 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for BCG therapy |
AU2017263833B2 (en) | 2016-05-13 | 2023-08-03 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
GB201612317D0 (en) | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
EP3562512A4 (en) | 2016-11-28 | 2020-12-23 | Indian Institute Of Technology, Delhi | FORMULATION FOR THE STABILIZATION OF BIOTHERAPEUTICS |
CN112618482A (zh) * | 2019-09-24 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | 新型蛋白制剂 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3637640A (en) * | 1970-05-04 | 1972-01-25 | Diagnostic Data Inc | Orgotein stabilized with saccharide process and products |
DE2652636A1 (de) * | 1976-11-19 | 1978-05-24 | Hans Uwe Dr Rer Nat Wolf | Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung |
DE3064888D1 (en) * | 1979-04-30 | 1983-10-27 | Hoechst Ag | Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization |
US4309418A (en) * | 1980-03-25 | 1982-01-05 | Sloan-Kettering Research Institute For Cancer | Anti-tumor agent from human serum and process |
-
1983
- 1983-08-19 US US06/524,540 patent/US4457916A/en not_active Expired - Lifetime
- 1983-08-23 IT IT67886/83A patent/IT1200970B/it active
- 1983-08-27 DE DE3331003A patent/DE3331003C2/de not_active Expired
- 1983-08-30 ES ES525228A patent/ES8706446A1/es not_active Expired
- 1983-08-31 FR FR8313971A patent/FR2532178B1/fr not_active Expired
- 1983-08-31 GB GB08323271A patent/GB2126588B/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
GB2126588A (en) | 1984-03-28 |
DE3331003A1 (de) | 1984-03-01 |
IT1200970B (it) | 1989-01-27 |
ES8706446A1 (es) | 1987-06-16 |
FR2532178B1 (fr) | 1986-07-04 |
US4457916A (en) | 1984-07-03 |
GB2126588B (en) | 1986-06-25 |
IT8367886A0 (it) | 1983-08-23 |
DE3331003C2 (de) | 1986-07-10 |
GB8323271D0 (en) | 1983-10-05 |
FR2532178A1 (fr) | 1984-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES525228A0 (es) | Un metodo para preparar una solucion acuosa estable que contiene factor de necrosis de tumores. | |
ES521266A0 (es) | Un metodo para preparar una solucion acuosa estable que contiene factor de necrosis de tumores. | |
ES531234A0 (es) | Un procedimiento para preparar una composicion acuosa estabilizada de un herbicida sulfonilurea. | |
ES516963A0 (es) | Procedimiento para preparar una solucion de insulina estabilizada. | |
ES528577A0 (es) | Procedimiento para preparar acidos 4-fenil-1,3-dioxan-cis-5-ilalquenoicos | |
ES496747A0 (es) | Un metodo para preparar una solucion acuosa de nitrogliceri-na | |
ES521728A0 (es) | Un procedimiento para la preparacion de una sal de adicion de un acido bencenosulfonico de la sultamicilina. | |
ES516482A0 (es) | "un metodo para preprar una composicion acuosa de humo liquido". | |
AR230634A1 (es) | Procedimiento para preparar una solucion para inyeccion | |
ES534202A0 (es) | Un procedimiento para preparar nuevos compuestos de cefem. | |
ES518130A0 (es) | Un procedimiento para preparar una composicion epoxidica curable. | |
ES530392A0 (es) | Un metodo para preparar derivados de 4-hidroxi-2-quinolona. | |
ES517459A0 (es) | Un procedimiento para preparar un dentifrico estable. | |
ES520364A0 (es) | Un procedimiento para preparar compuestos de cefem. | |
ES518758A0 (es) | Un procedimiento para preparar azetidinas. | |
ES538192A0 (es) | Un procedimiento para preparar un 2-bromo-6b-9a - difluoro-11b, 17a, 21-trihidroxi-1, 4-pregnadien-3, 20-diona-17, 21-diester | |
ES521813A0 (es) | Procedimiento para preparar alcohil-polisacaridos. | |
ES520531A0 (es) | Procedimiento para preparar tioeteres. | |
ES530347A0 (es) | Un metodo de preparar una composicion suavizante para tejidos. | |
ES524307A0 (es) | Procedimiento para preparar una olefina internamente insaturada. | |
ES519308A0 (es) | Un procedimiento para preparar una composicion mejorada de pintura en emulsion acuosa. | |
ES524772A0 (es) | Un procedimiento para preparar fenilanilinas-n.sustituidas. | |
ES519936A0 (es) | Un procedimiento para preparar derivados de pirimidona. | |
ES522716A0 (es) | Un procedimiento para preparar un derivado de pirazol. | |
ES511120A0 (es) | Procedimiento para preparar una emulsion refrigerante. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC2A | Transfer of patent |
Free format text: DAINIPPON PHARMACEUTICAL CO, LTD.(TITULAR AL 50%) |
|
FD1A | Patent lapsed |
Effective date: 20070404 |